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Abstract
Post traumatic stress disorder (PTSD) is a devastating disease that has high
morbidity and mortality. Despite therapy, almost half of patients with PTSD
will have chronic and devastating symptoms. The novel agent
methylnedioxymethamphetamine (MDMA) has shown promise in phase 3
clinical trials; and, investigation into other therapies is warranted given our
current treatment resistance. The objective of the research is to compare
the use of MDMA assisted psychotherapy to psychotherapy alone.

Introduction

• PTSD is characterized by the affected individual re-experiencing a traumatic
event through flashbacks, intrusive thoughts, or nightmares
• Significant impact on daily function, increased risk of comorbid psychiatric
diagnoses, increased risk of suicide
• Symptoms include hyperarousal, impulsivity, detachment, illusions, difficulty
concentrating, sleep disturbances, avoidance, withdrawal,
depersonaalization, derealization, etc
• Symptoms must be present > 1 month
• Mechanism is unknown
• US and Canada adult prevalence is 6-9 % of general population, with higher
prevalence in special populations such as Veterans, refugees, indigenous
people, non-binary people, front-line workers during the COVID pandemic
• Risk factors: female gender, race, low socioeconomic class, less education,
childhood adversity, poor social support, personal or familial psychiatric
history
• Current mainstay treatment is CBT, pharmacotherapy such as SSRIs show
some efficacy when treating comorbid anxiety/depression
• Despite therapy, half of patients will have chronic and devastating symptoms
• Clinician Administered PTSD Scale (CAPS) gold standard survey that measures
symptom severity

Results

Discussion

Table 1 compares the mean reduction in CAPS scores
between the control/placebo group compared to the
treatment groups. CAPS scores were measured before
treatment sessions and then 1-2 months following treatment,
which consisted of 2-3 therapy sessions with placebo or
MDMA. Two of the studies, Jerome at al and Jardim et al, only
evaluated the reduction in CAPS in a treatment group without
a control. All studies found statistically significant (p< 0.005)
reduction in CAPS scores for treatment groups except for
Oehen et al compared to the control groups, with no
statistically significant reduction in CAPS.
• 7/8 studies found a statistically significant reduction in
CAPS score in the treatment group

• Mithoefer et al: 6 randomized, double blind, controlled clinical trials.
56% of participants no longer met diagnostic criteria at treatment exit
and 67% at 12 month follow up
• No adverse events occurred including increased suicidality, QTC
prolongation, or abuse potential
• Most side effects included temporary somatic pains, sweating, or
feeling flushed
• Jardim et al: specifically in patients with PTSD from sexual assault. All
CAPS scores reduced greater than 30%
• Ponte et al: sleep quality improved significantly in the treatment group
vs control
• Gorman et al: double blinded study, improved post traumatic growth
inventory
• Fedduccia et al: non-tapered group had lower CAPS then taper group

Table 1. Comparison of Results

Study

Mithoefer et al
Jerome et al

Mean reduction Mean reduction
in CAPS post
in CAPS post
therapy, control
therapy,
treatment
-10.5
-30.4
N/A

-44.8

Mitchell et al

-13.9

-24.4

Jardim et al

N/A

-48

Ponte et al

-12.4

-34.0

Gorman et al

-12.8

-35.1

Oehen et al

-3.2

-15.6

Wagner et al

-15.0

-40.2

Methods
• Search Strategy
• Pub Med Database
• October 2021
• Key Terms= “PTSD and MDMA and CAPS”
• 15 resulting articles
• Inclusion and Exclusion Criteria
• Free articles
• Full text articles
• 11 articles total
• 8 articles selected based on relevance to research question,
design, and outcome measures
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Figure 1. Percentage of patients after 2 treatment sessions who no longer met diagnosis
criteria for PTSD using CAPS in the treatment group (left) vs control group (right)

Conclusion
MDMA assisted-psychotherapy shows promising results in the treatment
of patients suffering from PTSD with minimal side effects. There is a good
safety profile without any adverse events seen yet in current research.
There is sufficient evidence that CAPS score improvement following
MDMA-assisted psychotherapy is greater than psychotherapy alone.
Research comparing the use of MDMA assisted psychotherapy with SSRIs
and psychotherapy would be an interesting avenue for future research.
However, the benefits of patients needing only two to three therapy
sessions with MDMA compared to a much longer course of SSRIs, to be
taken daily, offers a more cost effective treatment approach for the
patient. There is also the potential for future drug development using the
pharmacological profile of MDMA.
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